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Abstract The optimal treatment strategy and outcome of non-
gastric marginal zone lymphoma (MZL) remains undefined.
The role of rituximab and fludarabine in MZL has not been
critically appraised and compared with conventional chemo-
therapy. We retrospectively analyzed 81 consecutive patients
with non-gastric MZL (mucosa-associated lymphoid tissue
lymphoma, n=66; splenic MZL, n=11; nodal MZL, n=4). As
a group, the treatment results were favorable, with an overall
response rate of 87% and a complete response (CR) rate of
73%. The CR rate was similar for conventional chemother-
apy, and rituximab- and fludarabine-containing regimens.
However, the relapse rate was significantly decreased in
rituximab- and fludarabine-containing regimens. The use of
rituximab and fludarabine was associated with acceptable
side effects. For splenic MZL, splenectomy was significantly
associated with a superior CR rate. Early stage, good
performance status, and low international prognostic index
risk scores significantly impacted on CR rate and survivals.
Rituximab and fludarabine were safe for non-gastric MZL
and resulted in more durable remissions.
Keywords Non-gastric marginal zone lymphoma .
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Introduction
The World Health Organization (WHO) classification of
lymphoid malignancies distinguishes between three
different subtypes of marginal zone B cell lymphomas:
splenic B cell marginal zone lymphoma (splenic MZL)
[1], extranodal marginal zone lymphoma of mucosa-
associated lymphoid tissue (MALT lymphoma) [2], and
nodal marginal zone lymphoma (nodal MZL) [3]. MZLs
are derived putatively from memory B cells that have
passed through the germinal center (post-germinal center
memory B cells) [4]. The lymphoma cells, similar to
their putative normal counterparts, possess a remarkable
capability to home to sites where they have undergone
antigenic stimulation, including MALT, the spleen, and
lymph nodes [5], accounting for the formation of
lymphomas in these sites. However, despite a common
cell origin, MZL originating at different anatomical sites
have distinct clinicopathologic features and treatment
outcome [1–3].
Infections or chronic inflammation may provide the
antigenic stimulation in the initial stages of lymphoma-
genesis. Relevant infections include Helicobacter pylori in
gastric MALT lymphoma, Campylobacter jejuni, Borrelia
burgdorferi, and Chlamydia psittaci in extranodal MZL,
and hepatitis C virus in splenic MZL [6]. Chronic
inflammation due to autoimmune diseases, commonly
involving Sjögren syndrome and Hashimoto thyroiditis,
also predisposes to extranodal MZL [6].
MZLs are considered low-grade lymphomas. Gastric
MALT lymphoma is the most common MZL. The
efficacy of H. pylori eradication and the subsequent
therapeutic strategies for gastric MZL have been well
defined [7]. For non-gastric MZL, however, the optimum
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treatment is less well established because most large series
contained a mixture of gastric and non-gastric MZL and
rarely analyzed these disease entities separately.
Two classes of drugs, rituximab and purine analogues
(including fludarabine and 2-chlorodeoxyadenosine), have
made a major positive impact on the treatment outcome of
low-grade lymphomas, particularly follicular lymphoma.
However, their efficacy in the management of MZL has
only recently been examined [8–11], although their role in
comparison with other conventional regimens is still
undefined.
In this study, we retrospectively analyzed a consec-
utive cohort of patients with non-gastric MZL in order
to define the clinicopathologic features and the role of
rituximab and the purine analogue fludarabine in
comparison with alkylating agents in the treatment of
these lymphomas. Although there is as yet no definitive
evidence that non-gastric MZL, splenic MZL, and nodal
MZL are distinctive diseases, increasing evidence sug-
gests that they have different clinicopathologic features
and treatment outcome. Therefore, they were also both
analyzed individually and together as a group in this
study.
Materials and methods
Patients
Consecutive patients with non-gastric MZL diagnosed
between January 1998 and January 2010 were analyzed.
There were no exclusion criteria. The diagnoses were based
on the WHO classification criteria of MZL [1–3].
Investigations and treatment
Standard staging procedures including bilateral bone
marrow trephine biopsies were adopted. Computerized
tomography, magnetic resonance imaging, or positron
emission tomography/computerized tomography was
used for the detection of organ or tissue involvement
at the primary site, thorax and abdomen. Treatment
regimens were determined at the discretion of the
attending physicians.
Statistical analysis
Response to treatment was determined by standard
criteria [12]. Overall survival (OS) was calculated from
the date of diagnosis to the date of death or last follow-up.
Disease-free survival (DFS) was calculated from the date
of achievement of complete response to date of death,
disease relapse/progression, or date of last follow-up.
Difference between treatment groups was calculated by
chi-square test. Prognostic factors for complete response
(CR) and mortality were identified with logistic regression
analysis. Five-year OS and DFS were estimated through
the Kaplan–Meier method, and comparisons between
treatment regimens were performed using Cox regression
analysis.
Results
Patients
Eighty-one patients were identified (Table 1). There was
no gender preference, with a median age of presentation at
57 (15–86)years. MALT lymphomas were most prevalent,
followed by splenic and nodal MZL. Patients predomi-
nantly presented with early-stage disease, with good
performance status and no B symptoms. Therefore, the
majority of patients had favorable International Prognostic
Index (IPI) scores. Paraproteins were present in 15 of 81
(18%) patients. About 20% of patients had a known
underlying autoimmune disease. Chronic hepatitis B virus
infection was found in 17% of patients, which was
comparable with the general population. Hepatitis C
infection was only found in one patient. Notably, two of
the patients were siblings, having splenic and nodal MZL,
respectively.
Non-gastric MALT lymphoma
Sixty-six patients had MALT lymphomas (Table 2).
Early-stage (stage I/II) disease was found in 80% of
patients. The most common sites of presentation were
ocular and ocular adnexal structures (29%), followed by
the salivary glands (20%). Multiple sites of involvement
were found in eight patients (12%). None of the patients
with ocular MALT lymphoma had autoimmune disor-
ders. However, seven patients with salivary gland (11%)
and two patients with thymic involvement (4%) had
underlying Sjögren syndrome. All four patients with
thyroid MALT lymphoma had autoimmune thyroiditis
with hypothyroidism. Autoimmune thyroid disease was
also found in a patient with skin MALT lymphoma.
Other associations were mixed connective tissue disease
in a patient with submandibular involvement and
Graves’ disease in a patient with conjunctival involve-
ment. Therefore, the frequency of autoimmune diseases
in this group of patient was 24% (16/66). A monoclonal
paraprotein was detected in 12 patients (18%). Whereas
immunoglobulin (Ig) M and G were found in MALT
lymphoma in various sites, IgA was detected only in
two patients with thymic involvement.
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Splenic MZL
Eleven patients (nine men, two women) had splenic MZL
(Table 3). Moderate splenomegaly (median size 10 cm
Table 1 Clinicopathological features of 81 patients with marginal
zone lymphoma
Clinicopathological features Number (%)
Gender
Male 38 (47)
Female 43 (53)
Median age (range), years 57 (15–86)
Diagnosis
Non-gastric MALT lymphoma 66 (81)
Splenic marginal zone B cell lymphoma 11 (14)
Nodal marginal zone lymphoma 4 (5)
Ann Arbor stage
I 41 (51)
II 13 (16)
III 5 (6)
IV 22 (27)
Presence of B symptoms 6 (7)
Performance status
0 46 (57)
1 21 (26)
2 11 (13)
3 3 (4)
4 0 (0)
International prognostic index
Low (0 or 1) 35 (43)
Low/intermediate (2) 23 (28)
Intermediate/high (3) 16 (20)
High (4 or 5) 7 (9)
Lactate dehydrogenase
Increased 65 (80)
Normal 14 (17)
Not available 2 (3)
Paraprotein
Immunoglobulin G 4 (5)
Immunoglobulin M 6 (7)
Immunoglobulin A 2 (2)
Two monoclonal antibodies 3 (4)
Not present 60 (74)
Not available 6 (7)
Hepatitis B virus infection
Positive 14 (17)
Negative 64 (79)
Not available 3 (4)
Concomitant autoimmune disorders
Present 18 (22)
Absent 63 (79)
Table 2 Clinicopathological features of 66 patients with non-gastric
MALT lymphoma
Clinicopathological features Number (%)
Gender
Male 27 (41)
Female 39 (59)
Median age (range), years 57 (15–86)
Primary site(s) of presentation
Ocular and ocular adnexae 19 (29)
Salivary gland 13 (20)
Buccal mucosa 2 (3)
Nasopharynx 1 (2)
Cricoid 1 (2)
Tonsils 1 (2)
Thyroid gland 4 (6)
Thymus 1 (2)
Lungs 6 (9)
Intestine 5 (8)
Omentum 1 (2)
Testes 1 (2)
Cutaneous 3 (5)
Two or more anatomical sites 8 (12)
Ann Arbor stage
I 41 (62)
II 12 (18)
III 4 (6)
IV 9 (14)
International Prognostic Index
Low (0 or 1) 55 (83)
Low/intermediate (2) 9 (14)
Intermediate/high (3) 2 (3)
High (4 or 5) 0 (0)
Paraprotein
Immunoglobulin G 3 (5)
Immunoglobulin M 4 (6)
Immunoglobulin A 2 (3)
Two monoclonal antibodies 3 (5)
Not present 49 (74)
Not available 5 (8)
Associated autoimmune diseases
Sjögren syndrome 9 (14)
Parotid MALT lymphoma 4 (6)
Submandibular MALT lymphoma 1 (2)
Minor salivary gland MALT lymphoma 2 (3)
Thymic MALT lymphoma 1 (2)
Multifocal MALT lymphoma involving also the thymus 1 (2)
Autoimmune thyroiditis with hypothyroidism 5 (8)
Thyroid MALT lymphoma 4 (6)
Cutaneous MALT lymphoma 1 (2)
Mixed connective tissue disease 1 (2)
Submandibular MALT lymphoma 1 (2)
Graves’ disease 1 (2)
Conjunctival MALT lymphoma 1 (2)
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below costal margin) was found in all the cases. There
were varying degrees of peripheral blood cytopenias.
Although neoplastic infiltration of the marrow was
observed in all patients, circulating lymphoma cells
were detectable in only six patients (55%). Monoclonal
immunoglobulin was detected in two patients (18%).
One patient was positive for lupus anticoagulant. In
one patient, the lymphoma cells were positive for CD5
with an absolute lymphocytosis of 10.8×109/L at
presentation.
Nodal MZL
There were four patients (two men, two women) with
NMZL. IgM monoclonal protein was detected in one
patient. In one patient, there was coexisting autoimmune
hemolytic anemia, vitiligo, and common variable immu-
nodeficiency diagnosed prior to the occurrence of
NMZL.
Treatment outcome of non-gastric MZL
Local therapy (excision with or without involved field
radiotherapy) was administered in 17 patients (26%).
Twenty-seven patients (41%) received systemic chemother-
apy. Twelve patients (18%) received rituximab-containing
chemotherapeutic regimens. Eight patients (12%) received
rituximab alone. The response rates for this group of
patients were presented in Table 4.
Splenic MZL
The treatment regimens and responses for this group of
patients were presented in Table 3. Splenectomy was
performed in five patients, which was followed by
chemotherapy in three patients and rituximab and chemo-
therapy in two patients. Six patients received chemother-
apy without splenectomy, one of whom received rituximab
as well. The CR rate was significantly better in patients
who were splenectomized as compared with those who
were not (CR: 4/5 splenectomized versus 1/6 non-
splenectomized, P=0.035).
Nodal MZL
Two patients were treated with the regimen fludarabine,
mitoxantrone, dexamethasone (FND): one patient with R-
FND (rituximab 375 mg/m2 before each course of FND)
and one patient with chlorambucil followed by rituximab
(375 mg/m2 given weekly for four doses). CR was achieved
in two patients and partial response (PR) in one patient.
Relapse characteristics and transformation
The features and outcome of relapsed cases of the non-
gastric, splenic, and nodal MZL were presented individu-
ally in Table 5. Fifteen patients with non-gastric MALT
lymphoma relapsed, three with high-grade histological
transformation. Ten patients underwent further treatment,
Table 3 Clinicopathologic features and treatment results of 11
patients with splenic marginal zone lymphoma
Parameters Number (%)
Gender
Male 9 (82)
Female 2 (18)
Median age (range), years 50 (35–80)
B symptoms 3 (27)
Splenomegaly 11 (100)
Median size (range), cm below left costal margin 10 (5 25)
Hepatomegaly 2 (18)
Hematological parameters
Anemia (Hb <11 g/dL) 7 (64)
Lymphocytosis (>4 × 109/L) 5 (45)
Neutropenia (<2 × 109/L) 2 (18)
Thrombocytopenia (<100×109/L) 5 (45)
Leukemic phase 5 (55)
Marrow infiltration 11 (100)
Paraproteinemia
IgG 1 (9)
IgM 1 (9)
International prognostic index
Low (0 or 1) 1 (9)
Low/intermediate (2) 3 (27)
Intermediate/high (3) 5 (45)
High (4 or 5) 2 (18)
Treatment and outcome
Splenectomy + chemotherapya 3 (27)
CR 2/3 (67)
PR 1/3 (33)
Splenectomy + rituximab + chemotherapya 2 (18)
CR 2/2 (100)
Chemotherapya 5 (45)
CR 1/5 (20)
NR 4/5 (80)
Chemotherapya + rituximab 1 (9)
PR 1/1 (100)
Ig immunoglobulin, CR complete response, PR partial response, NR
no response
a Chemotherapy included chlorambucil, FND (fludarabine, mitoxan-
trone, dexamethasone), CHOP (cyclophosphamide, doxorubicin,
vincristine, prednisolone), CEOP (cyclophosphamide, epirubicin,
vincristine, prednisolone), and M-BACOD (methotrexate, bleomycin,
doxorubicin, cyclophosphamide, vincristine, dexamethasone)
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with nine (90%) achieving a second CR. The only patient who
did not respond to treatment had small bowel and pleural
involvement, which at relapse showed transformation into
diffuse large B cell lymphoma. Of the nine cases achieving
CR2, two patients had subsequent relapses, presenting as
transformation into high-grade follicular lymphoma and
diffuse large B cell lymphomas. Both patients died ultimately
of refractory lymphoma despite intensive chemotherapy and
hematopoietic stem cell transplantation. Three patients with
splenic MZL relapsed, two of whom showed high-grade
histological transformation. Only one patient achieved a CR2
after intensive chemotherapy and allogeneic hematopoietic
stem cell transplantation. One patient with nodal MZL
relapsed as a high-grade lymphoma and achieved CR after
chemotherapy and ibritumomab tiuxetan therapy.
Toxicity of treatment
Grade 4 neutropenia and febrile neutropenia was encoun-
tered in 14 (17.3%) and 13 (16%) patients, respectively
(Table 6). Treatment-related mortality due to sepsis oc-
curred in two cases (2.5%). Therapy-related acute myeloid
leukemia developed in one patient with parotid MALT
lymphoma 6 years after diagnosis.
Prognostic factors
Treatment results of the entire group were shown in Table 7.
The overall response rate was 87% (69/79 patients) with a
CR of 73% (58/79 patients). Various regimens designed for
indolent lymphomas were used (Table 8). Fludarabine
regimens and non-fludarabine regimens did not impact on
CR rates. However, relapses were significantly reduced in
patients receiving fludarabine regimens as compared with
those receiving non-fludarabine regimens (3/23, 13% versus 9/
22, 41%, P=0.03). Interestingly, rituximab-containing regi-
mens and non-rituximab regimens also did not impact on CR
rates. However, relapses were significantly decreased in
patients receiving rituximab-containing regimens as com-
pared with those receiving non-rituximab regimens (2/21,
10% versus 10/24, 42%, P=0.015). Similarly, when these
regimens were analyzed according to whether fludarabine
and/or rituximab were used, the CR rates were comparable.
However, relapse rates were significantly lower in patients
receiving both rituximab and fludarabine as compared with
patients receiving none (P=0.008), while patients receiving
either rituximab or fludarabine showed intermediate results
(Table 8). The impact of stage, performance status, and IPI
risk score on response rates was evaluated using logistic
regression. Favorable prognostic factors for CR were early-
stage (stage I/II) disease (OR=3.11, P=0.039), good perfor-
mance status (≤1, OR=9.36, P<0.001), and low IPI risk
score (<3, OR=4.17, P=0.011). These factors, nevertheless,
did not impact on the relapse rates.
Survivals
The 5-year OS for the whole cohort was 84.6% (95%
confidence interval, CI=0.73–0.92; Fig. 1a) and the 5-year
DFS was 82.2% (95% CI=0.70–0.90; Fig. 1b). During the
follow-up period, 14 patients (non-gastric MZL, n=9;
splenic MZL, n=5) died: ten from refractory diseases, two
from treatment-related causes, one from therapy-related
leukemia, and one from unrelated causes. Prognostic factors
associated with a lower mortality included stage I/II disease
(odds ratio=0.08, P<0.001) and IPI risk score <3 (odds
ratio=0.09, P<0.001). No differences in survival or mortality
were observed between different treatment regimens.
Discussion
In this study, we have analyzed a cohort of MZL patients
separately according to whether they had non-gastric,
Table 4 Treatment and outcome of 66 patients with non-gastric
MALT lymphoma
Treatment and outcome Number (%)
Refused treatment or defaulted 2 (3)
Local resection only 11 (17)
CR 8/11 (73)
PR 0/11 (0)
NR 3/11 (27)
Radiotherapy alone 3 (5)
CR 3/3 (100)
PR 0/3 (0)
NR 0/3 (0)
Local resection + radiotherapy 3 (5)
CR 3/3 (100)
PR 0/3 (0)
NR 0/3 (0)
Rituximab ± local treatment 8 (12)
CR 7/8 (88)
PR 1/8 (12)
NR 0/8 (0)
Chemotherapy ± local treatment 27 (41)
CR 20/27 (74)
PR 5/27 (19)
NR 2/27 (7)
Rituximab + chemotherapy ± local treatment 12 (18)
CR 10/12 (83)
PR 2/12 (17)
NR 0/12 (0)
CR complete response, PR partial response, NR no response
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splenic, and nodal disease and also as a group for their
responses to treatment. The reason for analyzing three MZL
as a group with respect to treatment outcome is because
similar drugs and strategies are often employed in their
treatment. This series showed features characteristic of
MZL. There was a slight female predominance (women/
men=1.4:1), probably related to a higher frequency of
autoimmune diseases in women, which predisposes to
MZL. In fact, the association of non-gastric MALT
lymphomas with autoimmune diseases was clearly ob-
served [13, 14], including salivary gland and thymic MALT
lymphomas with Sjögren’s syndrome and thyroid MALT
lymphomas with autoimmune thyroiditis. The most com-
mon primary site was ocular and ocular adnexal structures,
followed by salivary glands and lungs, similar to previously
reported findings [15, 16]. About 30% of patients had stage
IV disease at presentation, often with multiple sites of
involvement, which is in contrast to gastric MALT
lymphomas that are usually localized [17].
For the whole cohort, treatment results were favor-
able, with CR achieved in 73% of patients. The impact
of surgical removal of the lymphoma, particularly in
localized non-gastric MALT lymphomas in the salivary
and thyroid glands, has not been fully evaluated. We
showed that splenectomy, even in our small series of
splenic MZL, had a significantly favorable impact on
CR. Splenectomy has traditionally been considered to be
an important first-line treatment for splenic MZL [18].
However, with the advent of effective drugs including
rituximab and fludarabine, the role of splenectomy has
Table 5 Clinicopathological features and outcome of 19 patients with
relapsed non-gastric marginal zone lymphoma
Clinicopathological features and outcome Number (%)
Non-gastric MALT lymphoma 15/66 (23)
Site of relapse
Same 8 (53)
Different 7 (47)
Pattern of relapse
Locoregional 8 (53)
Advanced/disseminated 7 (47)
Transformation
None 63/66 (95)
Diffuse large B cell lymphoma 2/66 (3)
High-grade follicular lymphoma 1/66 (2)
Treatment and outcome
Radiotherapy alone 1
CR 1/1 (100)
Radiotherapy+FND 1
CR 1/1 (100)
Excision+radiotherapy+rituximab 1
CR 1/1 (100)
Excision+R-COPP 1
CR 1/1 (100)
FND 2
CR 2/2 (100)
CEOP 1
CR 1/1 (100)
NOPP 1
NR 1/1 (100)
CEOP followed by autologous PBSCT
consolidation
1
CR 1/1 (100)
DHAP followed by autologous PBSCT
consolidation
1
CR 1/1 (100)
Splenic marginal zone lymphoma 3/11 (27)
Site of relapse
Same 3 (100)
Pattern of relapse
Advanced/disseminated 3 (100)
Transformation
Diffuse large B cell lymphoma 1/11 (9)
T cell-rich B cell lymphoma 1/11 (9)
Treatment and outcome
FND 1
PR 1/1 (100)
CEOP 1
NR 1/1 (100)
DHAP followed by matched sibling
allogeneic BMT
1
CR 1/1 (100)
Table 5 (continued)
Clinicopathological features and outcome Number (%)
Nodal marginal zone lymphoma 1/4 (25)
Site of relapse
Same 1 (100)
Pattern of relapse
Advanced/disseminated 1 (100)
Transformation 1/4 (25)
Diffuse large B cell lymphoma 1/4 (25)
Treatment and outcome
R-CEOP followed by 90Y-irbitumomab
tiuxetan consolidation
1
CR 1/1 (100)
CR complete response, PR partial response, NR no response, FND
fludarabine–mitoxantrone–dexamethasone, CEOP cyclophospha-
mide–epirubicin–vincristine–prednisolone, NOPP mitoxantrone–vin-
cristine–procarbazine–prednisolone, DHAP dexamethasone–
cytarabine–cisplatin, COPP cyclophosphamide–vincristine–procarba-
zine–prednisolone, PBSCT peripheral blood stem cell transplantation,
BMT bone marrow transplantation, R rituximab at 375 mg/m2 before
each course of chemotherapy
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been questioned [19]. In a recent series of splenic MZL,
the purine analogue 2-chlorodeoxyadenosine with or
without rituximab has been reported to result in a CR
rate of only 52%, very few of the patients having
undergone a splenectomy [11]. The role of splenectomy
might be clarified by a trial comparing splenectomy +
immunochemotherapy versus immunochemotherapy
alone. However, such a study is unlikely to be
performed because of the rarity of splenic MZL and
the general reluctance of using surgery to treat lympho-
ma patients. Hence, it may not be unreasonable to start
treatment with a combination of rituximab and a purine
analogue and reserve the more invasive splenectomy for
patients with unsatisfactory responses or relapses after
immunochemotherapy.
Similarly, although rituximab has significantly improved
the outcome of aggressive [20] and indolent [21] B cell
lymphomas, its role in MZL has not been critically
appraised. If fact, data of the impact of rituximab on the
outcome of MZL have not been well documented. Likewise,
whereas purine analogues have improved the treatment
outcome of low-grade lymphomas [22], their therapeutic
efficacy has only recently been examined in MZL. Combi-
nation treatment with rituximab and fludarabine had been
reported in two series [9, 23] comprising only 36 patients
with non-gastric MZL. The CR rate varied from 54% to
80%. In another series of 82 patients with non-gastric MZL,
the purine analogue 2-chlorodeoxyadenosine ± rituximab
resulted in a CR rate ranging from 60% to 73% [24].
However, none of these studies compared their results
with conventional regimens containing alkylating agents.
Therefore, whether rituximab and purine analogues
actually resulted in better outcome than alkylating
agents could not be determined. In fact, the European
Table 7 Treatment results of 79 patients with non-gastric marginal zone lymphomas
Treatment Number OR CR PR SD PD Relapse
Local treatment alone 17 14/17 (82%) 14/17 (82%) 0/17 (0%) 2/17 (12%) 1/17 (6%) 5/14 (36%)
Systemic chemotherapy
Fludarabine containing 28 25/28 (89%) 23/28 (82%) 2/28 (7%) 1/28 (4%) 2/28 (7%) 3/23 (13%)
Non-fludarabine containing 34 28/34 (82%) 22/34 (65%) 6/34 (18%) 3/34 (9%) 3/34 (9%) 9/22 (41%)
Rituximab
Rituximab ± chemotherapy 25 23/25 (92%) 21/25 (84%) 2/25 (8%) 1/25 (4%) 1/25 (4%) 2/21 (10%)
Non-rituximab-containing
chemotherapy
37 30/37 (81%) 24/37 (65%) 6/37 (16%) 3/37 (8%) 4/37 (11%) 10/24 (42%)
Fludarabine and rituximab
Fludarabine + rituximab containing 11 10/11 (91%) 10/11 (91%) 0/11 (0%) 0/11 (0%) 1/11 (9%) 0/10 (0%)
Fludarabine, non-rituximab containing 17 15/17 (88%) 13/17 (76%) 2/17 (12%) 1/17 (6%) 1/17 (6%) 3/13 (23%)
Rituximab, non-fludarabine containing 14 13/14 (93%) 11/14 (79%) 2/14 (14%) 1/14 (7%) 0/14 (0%) 2/11 (18%)
Non-fludarabine, non-rituximab 20 15/20 (75%) 11/20 (55%) 4/20 (20%) 2/20 (10%) 3/20 (15%) 7/11 (64%)
OR overall response, CR complete response, PR partial response, SD stable disease, PD progressive disease
Table 6 Therapy-related toxicities in 81 patients with non-gastric
marginal zone lymphomas
Toxicity Number (%)
Anemia
Grade 1 10 (12)
2 6 (7)
3 3 (4)
4 2 (3)
Neutropenia
Grade 1 5 (6)
2 4 (5)
3 10 (12)
4 14 (17)
Thrombocytopenia
Grade 1 1 (1)
2 3 (4)
3 4 (5)
4 8 (10)
Intracranial hemorrhage 1 (1)
Febrile neutropenia 13 (16)
Bacteraemia 9 (11)
Invasive fungal infections 1 (1)
Reactivation of tuberculosis 1 (1)
Localized herpes zoster 1 (1)
Disseminated herpes zoster 1 (1)
Reactivation of hepatitis B virus infection 1 (1)
Therapy-related acute myeloid leukemia 1 (1)
Miscellaneousa 4 (5)
Therapy-related mortality 2 (3)
a Including two cases of vincristine-related neuropathy, one case of
chlorambucil-related liver function derangement, and one case of
acute graft-versus-host disease of the skin after matched sibling bone
marrow transplantation
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Society for Medical Oncology guideline has stated that
for gastric MALT lymphoma at least, no clear evidence
in the literature exists to indicate the superiority of any
of these drugs [7].
Our study was retrospective so that treatment regimens
were very heterogeneous. Therefore, firm conclusions are
not possible. However, we had the opportunity of compar-
ing rituximab, fludarabine, and alkylating agent-containing
regimens in the treatment of MZL. We also showed that CR
rates were not different between regimens containing
alkylating agents, rituximab, fludarabine, and rituximab
+ fludarabine. The CR rates in our study varied from
65% to 91%, comparable with data reported previously
from regimens containing rituximab and purine ana-
logues [9, 10, 24]. However, we showed that relapse rates
were significantly different, with regimens containing ritux-
imab and fludarabine giving significantly fewer relapses. The
results suggested that the depth of remission, reflecting the
extent of clearance of lymphoma cells, might be better with
rituximab- and fludarabine-containing regimens.
Concerns have been expressed over the use of rituximab
and purine analogues in MZL. In one study, the combined
use of rituximab and fludarabine resulted in significant
hematologic toxicities (grade III, 77%; grade IV, 42%),
with 15% of patients developing delayed marrow toxicity
that resulted in death [9]. In this study, however, grade IV
toxicity appeared to be acceptable at about 15%, with
treatment-related-mortality at only 2%. Therefore, ritux-
imab + fludarabine appeared to be safe in our patient
population, in accordance with experience of the use of this
combination in chronic lymphocytic leukemia. Another
issue is the possibility of myelodysplastic syndrome related
to the use of purine analogues [7], particularly fludarabine
[25]. One patient in our series developed acute myeloid
leukemia 6 years after receiving FND. Hence, it is
important that patients who have received fludarabine
should have life-long follow-up.
In conclusion, we showed that non-gastric MZL as a
group showed favorable response to treatment. The use of
rituximab and fludarabine reduced the relapse rate as
compared with conventional chemotherapy. Therapy with
rituximab and fludarabine was associated with acceptable
side effects. These data obviously have to be interpreted in
light of the heterogeneity of patients and treatment in this
months
O
ve
ra
ll 
su
rv
iv
al
 
100 2000
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
a
b
months
D
is
ea
se
 fr
ee
 s
ur
vi
va
l 
100 2000
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Fig. 1 Survival of patients with marginal zone lymphoma. a Overall
survival. b Disease-free survival
Table 8 Impact of pretreatment characteristics on outcome in non-gastric marginal zone lymphomas
Pretreatment characteristics Number OR CR PR SD PD Relapse
Disease stage
Stage I/II disease 52 50/52 (96%) 44/52 (85%) 6/52 (12%) 1/52 (2%) 1/52 (2%) 13/44 (30%)
Stage III/IV disease 27 19/27 (70%) 14/27 (52%) 5/27 (19%) 4/27 (15%) 4/27 (15%) 6/14 (43%)
Performance status
≤1 65 60/65 (92%) 53/65 (82%) 7/65 (11%) 2/65 (3%) 3/65 (5%) 13/53 (25%)
>1 14 9/14 (64%) 5/14 (36%) 4/14 (29%) 3/14 (21%) 0/14 (0%) 1/5 (20%)
IPI score
<3 56 53/56 (95%) 46/56 (82%) 7/56 (13%) 2/56 (4%) 1/56 (2%) 15/46 (33%)
≥3 23 16/23 (70%) 12/23 (52%) 4/23 (17%) 3/23 (13%) 4/23 (2%) 4/12 (33%)
OR overall response, CR complete response, PR partial response, SD stable disease, PD progressive disease
1406 Ann Hematol (2011) 90:1399–1407
series. Therefore, the combination of rituximab and
fludarabine should be fully evaluated systemically in
prospective trials.
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